lactam bridge comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Depressants are psychoactive drugs that temporarily diminish the function or activity of a specific part of the body or mind. Colloquially, depressants are known as "downers", and users generally take them to feel more relaxed and less tense. Examples of these kinds of effects may include anxiolysis, sedation, and hypotension. Depressants are widely used throughout the world as prescription medicines and as illicit substances. When these are used, effects may include anxiolysis (reduction of anxiety), analgesia (pain relief), sedation, somnolence, cognitive/memory impairment, dissociation, muscle relaxation, lowered blood pressure/heart rate, respiratory depression, anesthesia, and anticonvulsant effects. Depressants exert their effects through a number of different pharmacological mechanisms, the most prominent of which include potentiation of GABA or opioid activity, and inhibition of adrenergic, histamine or acetylcholine activity. Some are also capable of inducing feelings of euphoria. The most widely used depressant by far is alcohol (i.e. ethanol). Stimulants or "uppers", such as amphetamines or cocaine, which increase mental or physical function, have an opposite effect to depressants. Depressants, in particular alcohol, can precipitate psychosis. A 2019 systematic review and meta-analysis by Murrie et al. found that the rate of transition from opioid, alcohol and sedative induced psychosis to schizophrenia was 12%, 10% and 9% respectively.
Ray McIntire (1918–1996), a chemical engineer of Dow Chemical, rediscovered a process first patented in the early 1930s by the Swedish inventor Carl Munters. According to the Science History Institute, "Dow bought the rights to Munters's method and began producing a lightweight, water-resistant, and buoyant material that seemed perfectly suited for building docks and watercraft and for insulating homes, offices, and chicken sheds." In 1944, Styrofoam was patented. Before 1949, the chemical engineer Fritz Stastny (1908–1985) developed pre-expanded PS beads by incorporating aliphatic hydrocarbons, such as pentane. These beads are the raw material for molding parts or extruding sheets. BASF and Stastny applied for a patent, which was issued in 1949. The molding process was demonstrated at the Kunststoff Messe 1952 in Düsseldorf. Products were named Styropor. The crystal structure of isotactic polystyrene was reported by Giulio Natta. In 1954, the Koppers Company in Pittsburgh, Pennsylvania, developed expanded polystyrene (EPS) foam under the trade name Dylite. In 1960, Dart Container, the largest manufacturer of foam cups, shipped their first order.
Gestation in bats ranges from around 40 days to eight months, correlating with the size of the species. In most bat species, females carry and give birth to a single pup per litter. A newborn bat pup can be up to 40 percent of the mother's weight, and the pelvic girdle of the female can expand during birth as the two halves are connected by a flexible ligament. Females typically give birth upright or horizontally, using gravity to make the process easier. The young emerges rear-first, possibly to prevent the wings from becoming tangled, and the female holds it in her wing and tail membranes. In many species, females give birth and raise their young in maternity colonies and may assist each other in birthing. Most of the care for a young bat comes from the mother, though in monogamous species, the father plays a role. Allo-suckling, where a female suckles another mother's young, occurs in several species. This may serve to increase colony size in species where females breed in their birth colonies. Young bats can fly after they develop their adult body dimensions and forelimb length. For the little brown bat, this occurs when they are eighteen days old. Weaning of young for most species takes place in under 80 days. The common vampire bat nurses its offspring beyond that, and young vampire bats achieve independence later in life than other species. This is probably due to the species's blood-based diet, as the female may not be able to feed on a nightly basis.
=== Environmental effects === Fluoxetine has been detected in aquatic ecosystems, especially in North America. There is a growing body of research addressing the effects of fluoxetine (among other SSRIs) exposure on non-target aquatic species. In 2003, one of the first studies addressed in detail the potential effects of fluoxetine on aquatic wildlife; this research concluded that exposure at environmental concentrations was of little risk to aquatic systems if a hazard quotient approach was applied to risk assessment. However, they also stated the need for further research addressing sub-lethal consequences of fluoxetine, specifically focusing on study species' sensitivity, behavioural responses, and endpoints modulated by the serotonin system. Fluoxetine – similar to several other SSRIs – induces reproductive behavior in some shellfish at concentrations as low as 10-10 M, or 30 parts per trillion. Since 2003, several studies have reported fluoxetine-induced impacts on many behavioural and physiological endpoints, inducing antipredator behaviour, reproduction, and foraging at or below field-detected concentrations. However, a 2014 review on the ecotoxicology of fluoxetine concluded that, at that time, a consensus on the ability of environmentally realistic dosages to affect the behaviour of wildlife could not be reached. At environmentally realistic concentrations, fluoxetine alters insect emergence timing. Richmond et al., 2019 find that at low concentrations it accelerates emergence of Diptera, while at unusually high concentrations it has no discernable effect.
While negotiating with Alpachi for the hostages' release, Umeko realizes the truth and clears his name, while her teammates rescue Alpachi's son and delete Goldom. Attika Alpachi is voiced by Bin Shimada. Shinnooian Hakutaku (シンノー星人ハクタク, Shinnō Seijin Hakutaku): A wise woman from Planet Shinoo, with knowledge of all space herbs, who occasionally assumes the form of a human teenage girl and possesses a third eye shaped like a red jewel. After the Dekarangers take her into their protective custody, she provides guidance to Sen-chan, becomes attracted to him, and raises money for their wedding. Hakutaku is voiced by Reiko Suzuki (鈴木 れい子, Suzuki Reiko) while her human form is portrayed by Narumi Konno (近野 成美, Kon'no Narumi). Bandarean Jeeva (バンダレ星人ジーバ, Bandare Seijin Jība): A physically imposing Oni-themed alien, and champion boxer in Durden's illegal fight club, from Planet Bandare. After consuming Durden's steroid, Megagesterine, and gaining wing-like horns on his arms and neck, Jeeva fights Hoji, who defeats him. Following this, Jeeva reformed and found work as the assistant director of a television station. Jeeva is voiced by Toshitsugu Takashina (高階 俊嗣, Takashina Toshitsugu). Slorpean Faraway (スロープ星人ファラウェイ, Surōpu Seijin Farawei): A small-time criminal from Planet Slorpe who resembles a ganguro girl and possesses proficient hacking skills.
Sources: en.wikipedia.org
In January 2026, Thomas Crosbie, an American military expert working at the Royal Danish Defence College, said that any attempt to seize Greenland would constitute a criminal act, and that Denmark, with the backing of its allies, would have the legal right to arrest any Americans involved in such actions and prosecute them under Danish criminal law. Danish troops in Greenland are legally obligated to defend Danish territory under military law. Under a 1952 standing order, Danish troops are ordered to "immediately take up the fight without waiting for, or seeking orders" in "the event of an attack on Danish territory". The Danish government confirmed in January 2026 that the order remains in place and that Danish soldiers would shoot back if Greenland is attacked. The Ministry of Defence said Danish troops would immediately respond to an invasion of Greenland with force and the chairman of the Defence Committee, Rasmus Jarlov, said Denmark would invoke Article 5 if attacked by the US. Jarlov said an American attack would mean war with Denmark and that retaliation would include deadly force. As of January 2026, Article 5 has been invoked only once in NATO history: in response to the September 11 attacks on the US in 2001, when Denmark volunteered "to fight alongside American soldiers in two different conflicts ... [deploying] tens of thousands of troops to Afghanistan and Iraq over two decades ... [suffering] the third-highest per capita casualty rate".
== Life and work == Emanuel Gil-Av was born 1916 in Pensa of Tzarist Russia. After the death of his father, a physician, the family moved first to Central Europe and in 1928 to Tel-Aviv, Israel, where Gil-Av attended High School. Gil-Av studied petroleum chemistry at the University of Strasbourg. In 1940 he escaped the German occupation to England where he worked at first in the chemical laboratory of Chaim Weizmann, followed by the Petrochemical Ltd. in Manchester. After World War II, he moved to Palestine and he joined the Daniel Sieff Institute in Rehovot which was later on to become the Weizmann Institute of Science. In 1951 he earned his PhD under the supervision of Ernst David Bergmann. In his study of oil shale deposits, Gil-Av developed complex-forming stationary phases employing silver(I) ions for selective olefin separations by gas chromatography (GC). In co-operation with the centre of peptide chemistry at the Weizmann Institute of Science, he developed methods of the gas-chromatographic resolution of racemic α-amino acids. By coating a glass capillary column with the chiral stationary phase (CSP) N-trifluoroacetyl-L-isoleucine lauryl ester, Gil-Av et al. carried out in 1966 the first gas-chromatographic enantioseparation of racemic amino acids as N-trifluoroacetyl-O-alkyl derivatives. Many racemic compounds, amenable for enantioselective interaction via hydrogen bonding with the CSP, could be analytically enantioseparated by GC.
After site-specific phosphorylation by CK1δ, the stability of PER2 is increased and half-life of PER2 is expanded. Furthermore, PER2 stability can be influenced by CK1δ T344A mutation and site-specific phosphorylation of CK1δ at Thr-347 by other intracellular kinases.
An unknown Elamite king (sometimes speculated to be Khita) is recorded as having signed a peace treaty, in Old Elamite language written in an Old Akkadian ductus, with Naram-Sin (not deified in the text), stating: "The enemy of Naram-Sin is my enemy, the friend of Naram-Sin is my friend". Old Elamite is poorly understood (all other texts being very short) as yet making interpretation of the text challenging. The text mentions about twenty gods, mostly Elamite but with a few Sumerian and Akkadian, including Inshushinak, Humban, Nahiti, Simut, and Pinikir. It has been suggested that the formal treaty allowed Naram-Sin to have peace on his eastern borders, so that he could deal more effectively with the threat from Gutium.
Dextran micelles are 10 to 100 nm sized amphiphilic polymeric particles which have the advantages of avoiding drug clearance by the kidneys and traveling through blood vessels. The core of these micelles are hydrophobic, allowing for loading of hydrophobic drugs into the micelle. The outer shell of the particles is hydrophilic, which allows for long circulation times in the blood. Dextran can be conjugated with other materials to form polymeric micelles including stearic acid and cholesterol to further improve sustained release of the loaded hydrophobic drug. The size of the micelles can be controlled by altering the ratio of stearic acid to dextran. Dextran micelles can also be formed from conjugation with polycaprolactone, folic acid, retinoic acid, and PLGA.
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.